Skip to content

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm Determined by Dynamic Analysis of Exhaled Breath Condensate.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00710255
Enrollment
8
Registered
2008-07-04
Start date
2007-10-31
Completion date
2009-07-31
Last updated
2016-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Exercise Induced

Keywords

Asthma, Exercise induced bronchospasm, Hyperpnea induced bronchospasm, leukotrienes, adenosine, exhaled breath condensate

Brief summary

This research is being conducted to help us better understand what causes exercise induced asthma. The investigators hypothesize that two types of chemicals, cysteinyl leukotrienes and adenosine, play an important role. The investigators will be measuring these chemicals in the exhaled breath of volunteers with exercise induced asthma as they undergo a test to mimic exercise induced asthma. The investigators will determine how the levels of these chemicals change in association with how lung function changes before, during and after an episode of exercise induced asthma.

Interventions

PROCEDUREHyperpnea challenge

5 minutes of dry air hyperpnea to induce bronchospasm

Sponsors

University of Vermont
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Physician diagnosed asthma * Age 12-75 yrs * FEV1 \> 70% predicted * HIB response \> 10 % * No smoking last 6 mo and \< 10 pack yrs * No URI last 4 weeks * No asthma exacerbation last 4 weks * Able to withhold SABA \> 8 hrs and LABA \> 24 hrs

Exclusion criteria

* Other lung disease * Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers

Design outcomes

Primary

MeasureTime frame
Change in level of cystLTs and adenosineBefore and after hyperpnea challenge

Secondary

MeasureTime frame
Change in pH of EBC and change in pulmonary functionBefore and after hyperpnea challenge

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026